664 related articles for article (PubMed ID: 31912450)
1. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
[TBL] [Abstract][Full Text] [Related]
2. The application of genome editing in studying hearing loss.
Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
[TBL] [Abstract][Full Text] [Related]
3. Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing.
Gu X; Wang D; Xu Z; Wang J; Guo L; Chai R; Li G; Shu Y; Li H
Genome Biol; 2021 Mar; 22(1):86. PubMed ID: 33752742
[TBL] [Abstract][Full Text] [Related]
4. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
5. Gene editing based hearing impairment research and therapeutics.
Kang W; Sun Z; Zhao X; Wang X; Tao Y; Wu H
Neurosci Lett; 2019 Sep; 709():134326. PubMed ID: 31195050
[TBL] [Abstract][Full Text] [Related]
6. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.
Gao X; Tao Y; Lamas V; Huang M; Yeh WH; Pan B; Hu YJ; Hu JH; Thompson DB; Shu Y; Li Y; Wang H; Yang S; Xu Q; Polley DB; Liberman MC; Kong WJ; Holt JR; Chen ZY; Liu DR
Nature; 2018 Jan; 553(7687):217-221. PubMed ID: 29258297
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9; A robust technology for producing genetically engineered plants.
Farooq R; Hussain K; Nazir S; Javed MR; Masood N
Cell Mol Biol (Noisy-le-grand); 2018 Nov; 64(14):31-38. PubMed ID: 30511631
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated correction of human genetic disease.
Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
[TBL] [Abstract][Full Text] [Related]
9. Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo.
Tao Y; Lamas V; Du W; Zhu W; Li Y; Whittaker MN; Zuris JA; Thompson DB; Rameshbabu AP; Shu Y; Gao X; Hu JH; Pei C; Kong WJ; Liu X; Wu H; Kleinstiver BP; Liu DR; Chen ZY
Nat Commun; 2023 Aug; 14(1):4928. PubMed ID: 37582836
[TBL] [Abstract][Full Text] [Related]
10. Advances in genome editing for genetic hearing loss.
Ding N; Lee S; Lieber-Kotz M; Yang J; Gao X
Adv Drug Deliv Rev; 2021 Jan; 168():118-133. PubMed ID: 32387678
[TBL] [Abstract][Full Text] [Related]
11. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
Liu C; Zhang L; Liu H; Cheng K
J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9 therapeutics for liver diseases.
Aravalli RN; Steer CJ
J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
[TBL] [Abstract][Full Text] [Related]
14. Exploring the potential of genome editing CRISPR-Cas9 technology.
Singh V; Braddick D; Dhar PK
Gene; 2017 Jan; 599():1-18. PubMed ID: 27836667
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
Zhang X; Wang L; Liu M; Li D
Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
[TBL] [Abstract][Full Text] [Related]
16. The CRISPR/Cas9 system and its applications in crop genome editing.
Bao A; Burritt DJ; Chen H; Zhou X; Cao D; Tran LP
Crit Rev Biotechnol; 2019 May; 39(3):321-336. PubMed ID: 30646772
[TBL] [Abstract][Full Text] [Related]
17. Advances in gene therapy hold promise for treating hereditary hearing loss.
Jiang L; Wang D; He Y; Shu Y
Mol Ther; 2023 Apr; 31(4):934-950. PubMed ID: 36755494
[TBL] [Abstract][Full Text] [Related]
18. Genome Engineering for Stem Cell Transplantation.
Argani H
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
[TBL] [Abstract][Full Text] [Related]
19. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
[TBL] [Abstract][Full Text] [Related]
20. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
